Charles River to make Casgevy; Rentschler extends collab with ‘major client’; Andelyn works with Ultragenyx

21 Dec 2023

Gene Therapy

Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more. Charles River Laboratories said Monday it will manufacture Vertex and CRISPR Therapeutics’ Casgevy, with its Memphis site having gone through audits by the FDA and EMA. CDMO RoslinCT also manufactures the gene editing therapy. CDMO Rentschler Biopharma said that it has a “ major client ” for its manufacturing site in Milford, MA, with the facility set to go live in the second half of next year. The manufacturer noted Wednesday it will produce its “longstanding” client’s clinical-stage protein therapeutic for cancer in the US, after previously producing the same asset in Laupheim, Germany, for early-phase investigation.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Ultragenyx Pharmaceutical, Inc.

Charles River Laboratories, Inc.

CRISPR Therapeutics AG

[+2]

Indications

Neoplasms

Targets

Drugs

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.